For delivering tumor cell-killing enzymes, scientists have devised a method in a way that protects the enzyme until it can do its work inside the cell.
In their study in mBioŪ, the online open-access journal of the American Society for Microbiology, researchers assembled microscopic protein packages that can deliver an enzyme called PEIII to the insides of cells. By attaching a protein called ubiquitin to the enzyme, they were able to protect it from degradation by the cell, allowing the enzyme to complete its mission. The results indicate that ubiquitin may be a useful addition to targeted toxins.
Although researchers have been developing tumor-directed "targeted toxins" for decades, their success has been hindered by technical problems, including inadequate tumor specificity, low efficiency of delivery to the interior of the cell (also called the cytosol), and other issues. In this study, researchers from the National Institute of Allergy and Infectious Diseases sought to improve the persistence of the enzyme in the cytosol.
The third component in the bundle was a new addition: ubiquitin, a small protein that is normally used by cells to target waste proteins for degradation. The researchers inserted ubiquitin in between the LFn and the PEIII, then tested the bundle on mice with tumors. The idea was to use the cell's own ubiquitin-cleaving enzymes to cut the ubiquitin off and free up the PEIII enzyme once it's inside the cell.
The system worked. Tumor growth was inhibited in mice treated with targeted toxins that either carried the wild-type ubiquitin or engineered ubiquitin without lysine residues in it, a change that should prevent it from being degraded by the cell. The addition of ubiquitin enhanced the ability of the PEIII enzyme to persist inside the cell thereby enhancing its potency. And the ubiquitin didn't seem to hinder the efficiency of delivering the PEIII inside the cell.
As an added bonus, the addition of ubiquitin reduced the toxicity of the targeted toxin to non-tumor tissues.
The authors point out that the use of ubiquitin linkers shows considerable promise and could be an effective strategy for enhancing the potency of tumor-targeting toxins for use in patients. In research currently underway, they are attempting to improve on the system by making changes to the ubiquitin that allow it to unfold appropriately inside the cell.